A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.

Fresh from a $400 million series A round, Kailera Therapeutics has shown off phase 2 data on an obesity candidate it believes ...

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

Eli Lilly forecast sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street ...

Nicole Albanese, PharmD, discusses the science behind weight-loss drugs, their potential to treat other addictions as well as ...

Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the ...

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

Pharmaceutical giants Eli Lilly and Novo Nordisk, makers of Zepbound and Wegovy, respectively, have filed lawsuits against medical spas, weight-loss clinics, and compounding pharmacies they accuse of ...

For weight loss, you're more likely to have your insurance plan pay for Zepbound, which has the same main ingredient as Mounjaro. The difference is that Mounjaro is for diabetes and Zepbound is for ...

Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, ...